Calidi Biotherapeutics is pioneering innovative cancer treatment technologies that leverage the power of stem cells and oncolytic viruses. Their primary platform, CLD-101, utilizes tumor-tropic neural stem cells (NSCs) engineered to deliver an oncolytic adenovirus specifically to tumor sites. This approach not only aims to directly kill cancer cells but also to stimulate a robust immune response against tumors that are typically resistant to conventional therapies. By transforming "cold" tumors, which evade immune detection, into "hot" tumors that the immune system can recognize and attack, Calidi's technology enhances the overall efficacy of cancer treatment.

In addition to CLD-101, Calidi is developing other platforms such as RTNova, which focuses on systemic virotherapy to target metastatic cancers. This technology aims to overcome immune clearance and improve therapeutic targeting across multiple tumor sites. The combination of these advanced delivery systems and oncolytic viruses positions Calidi at the forefront of immunotherapy, with the potential to significantly improve clinical outcomes for patients suffering from various difficult-to-treat cancers. Their ongoing clinical trials and research efforts underscore a commitment to redefining cancer treatment paradigms through innovative biotherapeutic solutions.

United States

Calidi Biotherapeutics is a clinical-stage biopharmaceutical company revolutionizing oncolytic viral therapies with stem cell-based platforms.

Calidi Biotherapeutics

Company Details